



December 18, 2023

Dear Alpha-1 community,

We are excited to share that we received regulatory approval of our clinical trial application and initiated dosing in our WVE-006 clinical program.

What is WVE-006?

- WVE-006 is an investigational drug designed to address lung and/or liver disease for those living with Alpha-1 Antitrypsin Deficiency (AATD). It is made up of oligonucleotides, which are short, single strands of RNA.
- WVE-006 aims to increase the amount of alpha-1 antitrypsin (AAT) protein in the body and decrease the amount of accumulated protein in the liver.

What is Alpha-1 Antitrypsin Deficiency (AATD)?

People living with AATD have a hereditary condition where their bodies release lower levels of AAT protein into the blood stream. The main role of AAT protein is to protect the lungs from being attacked by the body's own enzymes (proteins that help promote chemical reactions in the body).

In some people with ZZ AATD the AAT protein is not working properly, and the following may happen:

- There is less protein in the blood to protect the lungs, which can lead to lung disease.
- Protein can build up in the liver, which can lead to liver damage over time.

What is the WVE-006 clinical program?

The WVE-006 early clinical program has two parts:

- Part one includes healthy volunteers. We initiated dosing in this group in 2023.
- Part two includes individuals with AATD who inherited two genes that cause AATD, one from each parent. This is referred to as homozygous ZZ AATD. This part of the study will include individuals with ZZ AATD who do not have symptoms or have mild to moderate lung disease and/or mild liver disease. We plan to enroll this group in 2024.

We plan to share data from our clinical program in 2024, including data showing whether we are increasing the amount of AAT protein in people with AATD, as well as safety and how WVE-006 is tolerated.

Where is the study and how do I learn more?

More details about the WVE-006 clinical program will be available soon on www.clinicaltrials.gov and should be discussed with your doctor.

We are grateful to the Alpha-1 community, including the advocacy organizations, community advisors, study sites, and clinicians, for their continued partnership and support of this program.

Sincerely,

Chelley Casey
VP, Patient Advocacy